- Home
- BBN vs APLT Comparison
BBN vs APLT Comparison
Compare BBN & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BBN | APLT |
|---|---|---|
| Founded | 1983 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 38.1M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | BBN | APLT |
|---|---|---|
| Price | $16.75 | $0.13 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $1.25 |
| AVG Volume (30 Days) | 231.8K | ★ 8.7M |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | ★ 6.90% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,000,000.00 |
| Revenue This Year | N/A | $124.18 |
| Revenue Next Year | N/A | $66.67 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $14.33 | $0.10 |
| 52 Week High | $18.36 | $1.50 |
Technical Indicators
Market Signals| Indicator | BBN | APLT |
|---|---|---|
| Relative Strength Index (RSI) | 33.02 | 27.06 |
| Support Level | $16.84 | $0.10 |
| Resistance Level | $17.05 | $0.13 |
| Average True Range (ATR) | 0.18 | 0.02 |
| MACD | -0.07 | 0.02 |
| Stochastic Oscillator | 0.00 | 17.28 |
Price Performance
Historical ComparisonAbout BBN BlackRock Taxable Municipal Bond Trust of Beneficial Interest
BlackRock Taxable Municipal Bond Trust is a diversified, closed-end management investment company. Its investment objective is to seek high current income, with a secondary objective of capital appreciation.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.